A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
Phase 2 · Testing Zasocitinib · 1 site · Takeda
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
This study is testing Zasocitinib (a drug) as a possible treatment. Condition(s) listed: Crohn's Disease.
It is open-label: participants know what they are receiving.
Phase 2 studies test whether a treatment shows signs of working, and keep checking safety, in a larger group of people with the condition.
Who can join
- Ages 18 to 75
- Any sex
Some of the main requirements, copied from the record:
- Men and women aged 18 to 75 years can participate in the study.
- Must have been diagnosed with Crohn's disease (CD) at least 1 month (30 days) before study start.
- Must have received other treatments for CD earlier but no longer tolerate these treatments or the treatment no longer helps.
There are also 10 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 20 participants are expected to take part.
- Start date: 2026-08-13.
- Main results expected around 2028-03-30 (estimate from the record).
- 1 study site listed (1 marked recruiting) in United Kingdom.
Main thing being measured
- Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interests (AESIs) (From start of study drug administration up to follow-up (up to Week 16))
In the researchers’ words
Crohn's disease (CD) is a serious, long-term condition that can cause swelling (inflammation) and painful ulcers anywhere in the gut. This study will investigate whether zasocitinib can improve CD biology at the cellular and molecular level in adults.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Lead sponsor | Takeda |
| Enrollment | 20 (estimated) |
| Start date | 2026-08-13 |
| Primary completion (est.) | 2028-03-30 |
| First posted | 2026-02-11 |
| Last updated | 2026-08-24 |
| Official title | An Open-Label, Single-Arm, Phase 2a Trial to Evaluate the Safety, Tolerability, PK, and Mechanism of Action of Zasocitinib (TAK-279) in Participants With Active Crohn's Disease |
| ClinicalTrials.gov ID | NCT07403968 |
Interventions
- Zasocitinib (Drug)
Zasocitinib administered orally.
Full eligibility criteria (from the record)
Inclusion Criteria: 1. Men and women aged 18 to 75 years can participate in the study. 2. Must have been diagnosed with Crohn's disease (CD) at least 1 month (30 days) before study start. 3. Must have received other treatments for CD earlier but no longer tolerate these treatments or the treatment no longer helps. Exclusion Criteria 1. Cannot have another condition that causes swelling (inflammation) in the bowel. 2. Cannot have complications of CD which may require surgery. 3. Cannot have current abscesses or abscesses that have been treated within 6 weeks before study start. 4. Cannot have had a removal of parts of the bowel within half a year (6 months) before study start. 5. Cannot have had any surgery inside the belly (intraabdominal) within 3 months before study start. 6. Cannot have or had a J-pouch. 7. Cannot have had infections up to 2 months (8 weeks) before study start. 8. Cannot have given blood or plasma within 1 month (30 days) before study start. 9. Cannot tolerate having blood taken with a needle from a vein (venipuncture). Additional entry criteria will be discussed with the study doctor.
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Oxford Experimental Medicine Clinical Research Facility | Oxford | United Kingdom | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.